PEFLOXACINUM is a synthetic protivomikrobnoe mean of group of ftorkhinolonov. Possesses the wide spectrum of action, especially active in regard to aerobic gram-negative bacteria and staphylococcuss. Active also in regard to vnutrikletochnykh exciters. Effective in regard to gram-negative bacteria, being both in a state of division (phase of growth) and in the stage of rest (cellular associations are in the limited cavities, detritakh, abscesses, and also in tissue substratakh, encapsulating foreign bodies). Operates bactericidal, ingibiruya replikaciyu of DNA of bacteria, rendering influence on RNK and on the synthesis of albumen in microbal cages. Has a wide spectrum of antibacterial activity, here very active in regard to gram-negative bacteria and staphylococcuss. Shows activity in regard to microorganisms, steady to the action of other antimicrobial facilities. After peroral application quickly sucked in in a digestive highway; a maximal concentration in plasma of blood is marked through 90 mines after a reception. A half-period pefloksacina makes approximately 8 ch. Well gets to fabrics and organs (including in myocardium, CNS, mucous membrane of bronchial tubes, bone fabric). Hatches with urine and bile, mainly in the unchanged kind, partly as active metabolitov — dimetil-pefloksacina (norfloksacina), pefloksacin-N-oxides and pefloksacina glyukuronida. Unchanged pefloksacin and him metabolity it is possible to define in urine through 84 ch after introduction of the last dose.
TESTIMONIES: mono- or combined antibiotikoterapiya infections, caused sensible to to by pefloksacinu microorganisms: infections of urinary ways, and also prostatit; gynaecological infections; infections of respiratory tracts (including intensifying of chronic bronchitis, nozokomial'nye pneumonias, intensifying of respirator infections at mukoviscidoze); infections of organs of abdominal region (including the infections of zhelchevyvodyaschikh ways and heavy bacillosiss of digestive highway), transmitter of salmonellas; infections of bones and joints (including osteomielit, caused gram-negative microorganisms); infections of skin and soft fabrics; septicemiya; endocarditis; bacterial meningitis (at rezistentnosti of exciter to other antibiotics); gonorrhoea; treatment and prophylaxis of infections for patients with dysimmunities.
APPLICATION: middle day's dose for adults makes 800 mg/sut. Parenterally Abaktal appoint as slow (during 1 ch) v/v infuzii 2 times per days (each 12 ch). Content of one ampoule (400 mgs) is conducted in 250 mgs 5% glucose (as a solvent it is impossible to use r-r sodium of chloride or any solvent, containing the ions of chlorine). At a necessity rapid achievement of effective concentration of preparation in blood treatment is begun with introduction of initial dose by 800 mgs. To the patients with a parafunction liver preparation is appointed from a calculation by 8 mgs on 1 kg of mass of body as infuzii during 1 ch: at an icterus — 1 one time per days, at a hydroperitoneum — each 36 ch, at combination of icterus and hydroperitoneum — each 48 ch. Maximal day's dose makes 1200 mgs.
Perorally appoint for to a 1 pill 2 times per days (each 12 ch). At the infections of urinary ways appoint for to a 1 pill in days: at the uncomplicated infections during 3 days, at heavy infections — to 10–15 days. For the prophylaxis of relapses of infections of urinary ways preparation can be appointed for to a 1 pill 1 one time per a week. It is necessary to accept pills during a meal.
As a basic mechanism of leadingout of pefloksacina is a hepatic hovergap, for patients with parafunctions buds the leadingout of preparation practically does not change and there is not a necessity for the decline of dose. Pefloksacin does not hatch by gemodializa, therefore it is not required to enter an additional dose after his leadthrough. For patients with heavy hepatic insufficiency the leadingout of pefloksacina is considerably slowed, it is therefore necessary to reduce the recommended day's dose a to 400 mg on condition of determination of concentration of pefloksacina in the whey of blood.
CONTRA-INDICATIONS: enhanceable sensitiveness to pefloksacinu and other preparations of khinolonovogo row, period of pregnancy and suckling (risk of development at a fruit or new-born erosive defeat of cartilaginous fabric), children and teenagers (in connection with possibility of development of artralgiy).
SIDE EFFECTS: pefloksacin usually carried well, at a reception side effects, characteristic for preparations of group of khinolonov, — poorly expressed gastrointestinal'nye violations, myalgia, artralgiya, photosensibilization, head pain, insomnia, trombocitopeniya can be marked (at setting in the dose of 1600 mg/sut).
SPECIAL POINTING: during treatment of Abaktalom it is necessary to avoid influence of direct sunbeams and artificial ultraviolet. At appearance of cutireactions it is necessary to abolish treatment. Exposed to influence of direct sunbeams recommended not before what in 6 days after treatment. During treatment it is necessary to avoid the enhanceable physical loadings and use the enough body of liquid for providing of adequate hydratation. At determination of glucose in urine it is necessary to apply the fermentativnye methods of analysis, as a false-positive result can be marked at the use as a reagent of sulfate of copper.
CO-OPERATIONS: pefloksacin operates synergistically with beta-laktamnymi antibiotics. Preparation can be appointed in combination with metronidazolom and vankomicinom. Pefloksacin at simultaneous application with Tetracyclinum and chloramphenicol shows antagonism in their relation. In combination with rifampicinom pefloksacin can render a synergistic action in regard to staphylococcuss.
OVERDOSE: at setting in the dose of 1600 mg/sut and nausea, vomiting, entangled of consciousness, psikhoticheskie reactions, excitation, is more possible; in heavy cases are violations of consciousness and cramp. Appoint washing of stomach, absorbent carbon. It is necessary to support the necessary level of hydratation. Treatment is symptomatic, gemodializ is not the adequate method of leadingout of khinolonov from an organism.